Pinealon
Also known as: EDR peptide, Glutamylaspartylarginine, Glu-Asp-Arg
Overview
Pinealon is a synthetic tripeptide bioregulator (Glu-Asp-Arg) classified as a cytogen — a peptide that directly interacts with DNA to modulate gene expression rather than acting through classical receptor pathways. Developed by Professor Vladimir Khavinson from research on brain tissue extracts, particularly the pineal gland, it targets the central nervous system with multimodal neuroprotective activity. It influences mitochondrial enzyme activity, reduces lipid peroxidation, and has shown neuroprotective effects against various brain insults.
Mechanism of Action
Pinealon acts as a DNA-interacting cytogen, binding to specific gene promoters to modulate their expression. Unlike receptor-dependent peptides, it enters cells and the nucleus to influence chromatin structure and gene activity. Research suggests it affects mitochondrial enzyme activity relevant to brain energetics, modulates pineal gland function influencing melatonin signaling, and exerts neuroprotective effects through inhibition of lipid peroxidation and mitochondrial stress reduction. It appears distinct from Epithalon in mechanism and target tissue, with Pinealon focused on neuronal protection while Epithalon targets telomerase.
Potential Benefits
- Neuroprotective effects on brain cells against various insults
- Mitochondrial enzyme activity modulation in brain tissue
- Inhibition of lipid peroxidation reducing oxidative stress
- Potential memory and cognitive performance support
- Support for pineal gland function and melatonin rhythm
- Complementary to Cortagen (regenerative) in brain protection protocols
Dosage Protocols
The following reflects doses used in published research studies. This is not medical advice. Consult a qualified healthcare professional.
| Beginner | 100 mcg daily for 10 days |
| Intermediate | 150 mcg daily for 15 days |
| Advanced | 200 mcg daily for 20 days, repeat every 6 months |
| Cycle Duration | 10-20 days (Russian bioregulator protocol) |
Khavinson short peptide (Glu-Asp-Arg). Used in cyclic protocols similar to Epithalon.
Use our Reconstitution Calculator to determine exact syringe units for your protocol.
Routes of Administration
Subcutaneous Injection High
Primary route in Russian bioregulator protocols.
Intranasal Moderate CNS delivery
Used for cognitive/neuroprotective targeting.
Read our full Routes of Administration Guide for detailed comparison of all delivery methods.
Stacking Protocols
Popular research stacks involving Pinealon:
Bioregulator Anti-Aging Stack
Khavinson protocol. Pinealon for brain, Epithalon for pineal/telomere, Vilon for immune. 10-20 day cycles, 1-2x yearly.
Explore our complete Peptide Stacking Guide for more combinations and safety considerations.
Reconstitution
| Storage | Refrigerate at 2-8°C after reconstitution. Do not freeze reconstituted solution. |
|---|
Typical vial sizes: 2-10 mg. Add bac water slowly down the side of the vial, swirl gently — do not shake. Use insulin syringe for precise dosing.
Need exact syringe measurements?
Amino Acid Sequence
Glu-Asp-Arg (EDR)
Side Effects & Safety
- Generally well-tolerated in available studies
- No major adverse events reported
Safety & Contraindications
This information is for educational purposes only. Consult a qualified healthcare provider before using any peptide.
Pregnancy / Lactation
Bleeding Disorders
Active Skin Infection at Injection Site
Pharmacokinetics
| Half-Life | Not well characterized for this peptide; consult primary literature |
|---|---|
| Storage | Store lyophilized peptide at -20°C (long-term) or 2-8°C (short-term, under 30 days). Reconstituted: refrigerate at 2-8°C and use within 28-30 days. Protect from light. Do not freeze reconstituted solution. |
Synergistic Compounds
The following compounds have been studied alongside Pinealon for potential complementary or synergistic effects:
Learn More
References & Further Reading
Latest News & Research
View all articles →
FDA PCAC July 2026: What the BPC-157 peptide compounding review really means
FDA’s Pharmacy Compounding Advisory Committee will review seven unapproved peptides in July 2026. What that process means for BPC-157—and what it doesn’t.
FDA signals enforcement against unapproved compounded GLP-1 drugs: what it means for peptide medicine
The FDA says it will restrict GLP-1 APIs used in mass-marketed unapproved compounded drugs and crack down on advertising that calls them generic versions of branded drugs.
Sublingual compounded peptides: Quicksome claims and what the FDA’s July 2026 PCAC review could change
A press release claims needle-free, sublingual delivery for popular compounded peptides—just as the FDA's PCAC prepares a July 2026 review of seven peptides.
Pemvidutide IMPACT 48-Week MASH Data Lands At EASL 2026 Ahead Of Phase 3
Altimmune's pemvidutide hit 32.4% ELF response, 23.7% triglyceride drop, and 54.5% qFibrosis regression in 212-patient F2/F3 MASH IMPACT Phase 2b at EASL 2026.